Skip to main content

Steven Horwitz, MD

Steven Horwitz, MD

Associate Attending, Department of Medicine
Medical Oncologist, Lymphoma Specialist and Cellular Therapist
Memorial Sloan Kettering Cancer Center (MSKCC)
New York, New York

Related Videos

As you suggest the current survival and cure metrics for PTCL are far from being optimized. How do the survival rates distribute to specific PTCL subtypes, and what are the treatment options based on a stratification into PTCL-TFH and subtypes?

As you suggest the current survival and cure metrics for PTCL are far from being optimized. How do the survival rates distribute to specific PTCL subtypes, and what are the treatment options based on a stratification into PTCL-TFH and subtypes?

Given the heterogeneity of PTCL—in particular, the differential outcomes based on subtype classification—what is the evidence and rationale for moving away from a “one treatment fits all” approach?

Given the heterogeneity of PTCL—in particular, the differential outcomes based on subtype classification—what is the evidence and rationale for moving away from a “one treatment fits all” approach?

Can you share how you made the “therapeutic and evidence-based” handshake between the dual delta-gamma PI3K inhibitor, duvelisib, and subsequent evaluation in patients with PTCL-TFH; and what you learned from PRIMO Phase 2?

Can you share how you made the “therapeutic and evidence-based” handshake between the dual delta-gamma PI3K inhibitor, duvelisib, and subsequent evaluation in patients with PTCL-TFH; and what you learned from PRIMO Phase 2?

In light of the adoption of duvelisib for R/R patients with PTCL-FTH disease, how do you view the current and future clinical approaches that might deploy this treatment in this patient population?

In light of the adoption of duvelisib for R/R patients with PTCL-FTH disease, how do you view the current and future clinical approaches that might deploy this treatment in this patient population?

What trial-based evidence did you and your colleagues generate beyond the PRIMO study that evaluated the efficacy, safety, and dosing of duvelisib, a dual delta gamma PI3K inhibitor in PTCL-TFH?

What trial-based evidence did you and your colleagues generate beyond the PRIMO study that evaluated the efficacy, safety, and dosing of duvelisib, a dual delta gamma PI3K inhibitor in PTCL-TFH?

In light of the evidence for duvelisib in R/R PTCL-TFH as well as its use for bridging to allograft bone transplantation, what can specialists draw on to guide their use of duvelisib-centric regiments in R/R patients?

In light of the evidence for duvelisib in R/R PTCL-TFH as well as its use for bridging to allograft bone transplantation, what can specialists draw on to guide their use of duvelisib-centric regiments in R/R patients?

Professor Horwitz, can you please give us a general introduction to the subtype-specific landscape of PTCL, with a focus on nodal PTCL-TFH—T follicular helper phenotype?

Professor Horwitz, can you please give us a general introduction to the subtype-specific landscape of PTCL, with a focus on nodal PTCL-TFH—T follicular helper phenotype?

Once the PTCL-TFH subtype is confirmed, what is typically the treatment roadmap? What treatment responses can be expected? What percentage is predicted to relapse and/or have resistant (R/R) disease?

Once the PTCL-TFH subtype is confirmed, what is typically the treatment roadmap? What treatment responses can be expected? What percentage is predicted to relapse and/or have resistant (R/R) disease?

How should clinicians approach duvelisib use in PTCL-TFH regarding dosing, monotherapy vs combination, and its role as a bridging agent to allogeneic transplant?

How should clinicians approach duvelisib use in PTCL-TFH regarding dosing, monotherapy vs combination, and its role as a bridging agent to allogeneic transplant?